Successful Treatment With Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A Case Report.

Content Provider	Europe PMC
Author	Toscano Peña, Andrés Ali Munive, Abraham Arevalo, Yaicith
Editor	Muacevic, Alexander Adler, John R
Copyright Year	2023
Abstract	Eosinophilic granulomatosis with polyangiitis (EGPA) is an uncommon antineutrophil cytoplasmatic antibody (ANCA) associated vasculitis involving small and medium size blood vessels. It has a variable clinical presentation depending on the main organ involved, making it difficult to diagnose. Treatment is mainly based on high-dose steroids and other immunosuppressants like cyclophosphamide, which may prevent end-organ damage and induce remission at the expense of having important adverse effects. However, new therapeutic agents had been shown to provide better results with favorable safety profiles. Biologic therapy with monoclonal antibodies such as Rituximab and Mepolizumab has been approved for its use in ANCA vasculitis including eosinophilic granulomatosis with polyangiitis. These cases describe two patients with EGPA whose initial presentation was severe asthma and who appeared to have extrapulmonary end-organ damage. Mepolizumab was used in both cases with a successful response.
Journal	Cureus
Volume Number	15
DOI	10.7759/cureus.38797
PubMed Central reference number	PMC10250110
Issue Number	5
PubMed reference number	37303316
e-ISSN	21688184
Language	English
Publisher	Cureus
Publisher Date	2023-05-09
Publisher Place	Palo Alto (CA)
Access Restriction	Open
Subject Keyword	anca- associated vasculitis mepolizumab severe asthma eosinophilic granulomatosis with polyangiitis churg strauss syndrome
Content Type	Text
Resource Type	Case study
Subject	Medicine